Lionetti E, Miniello V L, Castellaneta S P, Magistá A M, de Canio A, Maurogiovanni G, Ierardi E, Cavallo L, Francavilla R
Department of Biomedicina dell'Età Evolutiva, Università degli Studi di Bari, Bari, Italy.
Aliment Pharmacol Ther. 2006 Nov 15;24(10):1461-8. doi: 10.1111/j.1365-2036.2006.03145.x. Epub 2006 Oct 10.
Helicobacter pylori eradication fails in about 25-30% of children, particularly because of the occurrence of resistance to antibiotics and side-effects.
To determine whether adding the Lactobacillus reuteri to an anti-H. pylori regimen could help to prevent or minimize the gastrointestinal side-effects burden in children.
Forty H. pylori-positive children (21 males; median age: 12.3 years) were consecutively treated with 10-day sequential therapy [omeprazole + amoxycillin for 5 days, and omeprazole + clarithromycin + tinidazole for other 5 days] and blindly randomized to receive either L. reuteri ATCC 55730 (10(8) CFU) or placebo. All children completed the Gastrointestinal Symptom Rating Scale (GSRS) at entry, during and after treatment. H. pylori status was assessed after 8 weeks by (13)C-urea breath test.
Overall, in all probiotic supplemented children when compared with those receiving placebo there was a significant reduction of GSRS score during eradication therapy (4.1 +/- 2 vs. 6.2 +/- 3; P < 0.01) and at the end of follow-up (3.2 +/- 2 vs. 5.8 +/- 3.4; P < 0.009). Overall, children receiving L. reuteri report less symptoms than those receiving placebo.
L. reuteri is capable of reducing frequency and intensity of antibiotic-associated side-effects during eradication therapy for H. pylori.
幽门螺杆菌根除治疗在约25%-30%的儿童中失败，尤其是由于抗生素耐药性的出现和副作用。
确定在抗幽门螺杆菌治疗方案中添加罗伊氏乳杆菌是否有助于预防或减轻儿童胃肠道副作用负担。
40名幽门螺杆菌阳性儿童（21名男性；中位年龄：12.3岁）连续接受10天序贯疗法[奥美拉唑+阿莫西林治疗5天，奥美拉唑+克拉霉素+替硝唑治疗另外5天]，并被随机分为接受罗伊氏乳杆菌ATCC 55730（10⁸CFU）或安慰剂。所有儿童在治疗开始时、治疗期间和治疗后均完成胃肠道症状评分量表（GSRS）。8周后通过¹³C-尿素呼气试验评估幽门螺杆菌感染状况。
总体而言，与接受安慰剂的儿童相比，所有补充益生菌的儿童在根除治疗期间（4.1±2 vs. 6.2±3；P<0.01）和随访结束时（3.2±2 vs. 5.8±3.4；P<0.009）的GSRS评分显著降低。总体而言，接受罗伊氏乳杆菌的儿童报告的症状少于接受安慰剂的儿童。
罗伊氏乳杆菌能够降低幽门螺杆菌根除治疗期间抗生素相关副作用的频率和强度。
